Table 2.
Biological pathways significantly enriched in differentially regulated proteins from SNCA-OVX mice
| Pathway name | Pathway enrichment –log (p) | Ratio of pathway constituents altered | Altered pathway components in dataset |
|---|---|---|---|
| Proline degradation | 3.48E + 00 | 1.00E + 00 | ALDH4A1, LOC102724788/PRODH |
| Oxidative phosphorylation | 3.08E + 00 | 8.33E-02 | NDUFB7, NDUFS6, MT-CO2, UQCRQ, NDUFB3, NDUFB10, NDUFS4 |
| Mitochondrial dysfunction | 3.02E + 00 | 6.52E-02 | NDUFB7, NDUFS6, NDUFAF2, MT-CO2, UQCRQ, NDUFB3, NDUFB10, VdAC2, NDUFS4 |
| Methylmalonyl pathway | 3.01E + 00 | 6.67E-01 | PCCA, MUT |
| Tryptophan degradation X (mammalian, via tryptamine) | 2.83E + 00 | 2.31E-01 | ALDH4A1, ALDH3A2, DDC |
| 2-oxobutanoate degradation I | 2.71E + 00 | 5.00E-01 | PCCA, MUT |
| Glutamate degradation III (via 4-aminobutyrate) | 2.50E + 00 | 4.00E-01 | GAD2, SUCLG2 |
| Huntington's disease signaling | 2.42E + 00 | 4.98E-02 | TGM2, GNB4, CAPNS1, CLTB, HSPA1A/HSPA1B, PLCB1, CAPN2, GNG3, STX1A, HSPA2 |
| Amyotrophic lateral sclerosis signaling | 2.25E + 00 | 6.74E-02 | PRPH, RAB5A, CAPNS1, NEFL, NEFH, CAPN2 |
| Fatty acid β-oxidation I | 2.15E + 00 | 1.36E-01 | ECI2, SLC27A1, ACADM |
| Acute phase response signaling | 2.05E + 00 | 5.47E-02 | HPX, C3, APOA1, TF, CP, SERPINA3, KRAS |
| Histamine degradation | 1.96E + 00 | 2.22E-01 | ALDH4A1, ALDH3A2 |